Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
NCT07566585Phase 1Withdrawn
- Sponsor
- BlueSphere Bio
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BSB-2002 in acute myeloid leukemia (AML) (2 arms), sponsored by BlueSphere Bio. Primary endpoint: Number of participants with dose-limiting toxicity, adverse events (AEs) and serious AEs (SAEs) at 365 days. Planned start Apr 2026; status: withdrawn.
02
Drugs
BSB-2002
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07566585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566585.